Skip to content
  • User-friendly
  • Needle-free
  • Reliable
  • Home
  • Affordable
  • Convenient
  • Cyclops™
Menu
  • User-friendly
  • Needle-free
  • Reliable
  • Home
  • Affordable
  • Convenient
  • Cyclops™

Carduso Capital invests in PIMS-E

Carduso Capital invests in PIMS-E, a Spin-off company of the University of Groningen that aims to develop an epinephrine dry powder inhaler as alternative to Epipen™.

More info

SHARE THIS POST

RECENT POSTS​

PIMS-E, a Subsidiary of PureIMS, Announces Results of a Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhaler for Early Intervention in Allergic Reactions and Anaphylaxis

PIMS-E, a subsidiary of PureIMS, completes Dosing in Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhalation Device for Early Intervention in Allergic Reactions and Anaphylaxis

Carduso Capital invests in PIMS-E

Cyclops as example of the TopDutch pioneering and collaborating mentality

CATEGORIES

Categories
  • News (2)
  • Press release (2)

Contact Us

Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com

Social media

Linkedin Youtube

Making Inhaling Easier

CALL US NOW
© 2019 pims-e
  • Facebook
  • Twitter
  • LinkedIn
  • Email